5
1 MiR-126 Regulates Growth Factor Activities and Vulnerability to Toxic Insult in Neurons [miR-126 and growth factor signaling in neurons] Woori Kim 1 , Haneul Noh 2 , Yenarae Lee 1 , Jeha Jeon 2 , Arthi Shanmugavadivu 1 , Donna L. McPhie 1 , Kwang-Soo Kim 1 , Bruce M. Cohen 1 , Hyemyung Seo 2 , Kai C. Sonntag 1 * 1 Department of Psychiatry, McLean Hospital, Harvard Medical School, Belmont, Massachusetts 02478 2 Department of Molecular and Life Sciences, Hanyang University, Seoul, Korea *Correspondence to: Kai-Christian Sonntag, M.D., Ph.D., Department of Psychiatry, McLean Hospital, Harvard Medical School, MRC 223, 115 Mill Street, Belmont, MA 02478, Phone: 617-855-3138, Fax: 617-855-3793, e.mail: [email protected] Supplementary Material

MiR-126 Regulates Growth Factor Activities and …10.1007...1 MiR-126 Regulates Growth Factor Activities and Vulnerability to Toxic Insult in Neurons [miR-126 and growth factor signaling

Embed Size (px)

Citation preview

1

MiR-126 Regulates Growth Factor Activities and Vulnerability to Toxic Insult in Neurons [miR-126 and growth factor signaling in neurons] Woori Kim1, Haneul Noh2, Yenarae Lee1, Jeha Jeon2, Arthi Shanmugavadivu1, Donna L. McPhie1, Kwang-Soo Kim1, Bruce M. Cohen1, Hyemyung Seo2, Kai C. Sonntag1* 1Department of Psychiatry, McLean Hospital, Harvard Medical School, Belmont, Massachusetts 02478 2Department of Molecular and Life Sciences, Hanyang University, Seoul, Korea *Correspondence to: Kai-Christian Sonntag, M.D., Ph.D., Department of Psychiatry, McLean Hospital, Harvard Medical School, MRC 223, 115 Mill Street, Belmont, MA 02478, Phone: 617-855-3138, Fax: 617-855-3793, e.mail: [email protected] Supplementary Material

2

Supplementary Fig. 1 Experimental outline, and Aβ1-42 toxicity. (a) Schematic of experimental outline. Neuronal cultures were transduced with virus vectors that express miR-126, NGF, sAPPα, or GFP from the Synapsin, phosphoglycerine kinase (PGK), or chicken beta actin (CAG) promoter, and treated with IGF-1, the IGF-1R inhibitor AG1024, STS, and Aβ1-42 oligomers. Neurotoxicity and neuroprotection were measured by LDH assays. (b) Aβ1-42 oligomers were produced as described in Material and Methods and analyzed by Western blot using the 6E10 antibody. (c) Aβ1-42 was neurotoxic in a dose-dependent manner in naïve, Syn.GFP, and Syn.miR-126 transduced cortical neurons. *: p < 0.05 comparing miR-126 to Syn.GFP controls. (d) Lenti.PGK.sAPPα-mediated expression of sAPPα was tested in PC12 neuroblastoma cells by Immunocytochemistry and Western blot using the 6E10 antibody. sAPPα was expressed intracellular (upper panel) and released into the media (lower panel).

a

day

0 6 17

Syn.miR-126 CAG.NGF PKG.sAPPα"Syn.GFP

- Insulin

STS Aβ1-42"

Aβ1-42 LDH"

19

+/- IGF-1 +/- AG1024

18

STS LDH"

11 Oligomers

Monomer

Aβ1-42 (1µM)

Syn. GFP

Syn. miR-126

- + - +

b

c d

PC12 naïve

PGK GFP

anti-sAPP!/DAB

PGK sAPP!

green fluorescence

MOCK PGK GFP

PGK sAPP!

30

50

70

90

0 0.1 1 10

Naïve Syn.GFP Syn.miR126

% C

ell D

eath

Rel

ativ

e to

1%

Trit

on-X

Con

trol

Aβ1-42 (µM)

* *

*

*

3

Supplementary Fig. 2 Quantification of apoptotic cell death. Left panel: Cells were stained with Tuj1 (anti-βIII-tubulin) and Hoechst, and apoptotic neurons quantified. Arrows depict viable and arrow heads apoptotic neurons. Size bar = 20 µm. Right panel: The percentage of apoptotic neurons relative to all apoptotic cells was increased in the miR-126 condition. *: p < 0.05 comparing miR-126 to Syn.GFP controls.

Tuj1

overlay

Hoechst

0

40

80

120

160

Naïve Syn.GFP Syn.miR-126

% A

popt

otic

Neu

rons

STS (nM)

- + - + - + 25 50 100

IGF-1

* * * * * *

4

Supplementary Fig. 3 Aβ1-42 toxicity and neuroprotective effects of IGF-1 and NGF in cortical and hippocampal neurons. (a-b) No difference in Aβ1-42 toxicity and IGF-1 or NGF protection was observed between naïve and PGK.GFP transduced cortical (a) and hippocampal neurons (b). (c) LDH assays showed that overexpression of miR-126 is neurotoxic and increases the toxic effects of Aβ1-42 in hippocampal neurons. IGF-1, NGF, and sAPPα protected hippocampal neurons against Aβ1-42 toxicity in both virus control and miR-126 transduced neurons with an accumulating effect of sAPPα in combination with IGF-1 and NGF. *: p < 0.05 comparing IGF-1 treated to IGF-1 untreated condition. #: p < 0.05 comparing Syn.miR-126 to Syn.GFP control.

a b

c

80

120

160

200

240

280

- + - - + - - + - - + -

- - + - - + - - + - - +

- - - + + + - - - + + +

- - - - - - + + + + + +

Syn.GFP Syn.miR-126

PGK.sAPPα"

% C

ell D

eath

Rel

ativ

e to

Unt

reat

ed V

irus

Con

trol

CAG.NGF IGF-1

Aβ1-42

* * *

*

* * * *

* *

* * * *

*

* * *

#

# #

#

# # #

# #

#

# #

*

*

CAG.NGF IGF-1

Aβ1-42

% C

ell D

eath

Rel

ativ

e to

Trit

on-X

Con

trol

20

40

60

- + - - + -

- - + - - +

- - - + + +

Naïve Syn.GFP

CAG.NGF IGF-1

Aβ1-42

% C

ell D

eath

Rel

ativ

e to

Trit

on-X

Con

trol

20

40

60

- + - - + -

- - + - - +

- - - + + +

Naïve Syn.GFP

5

Supplementary Fig. 4 Analysis of protein expression in factor-treated and virus-transduced cells. Semi-quantitative Western blots for measuring expression levels of IRS-1 and p85β (a), and AKT, pAKT, ERK, pERK, GSK-3β, and pGSK-3β (b) in Syn.GFP or Syn.miR-126 transduced neurons treated with Aβ1-42 and NGF or sAPPα. IRS-1 was upregulated in Aβ1-42 and NGF or sAPPα treated neurons, but downregulated or unchanged, when miR-126 was overexpressed. Expression levels of p85β were also increased in controls, but to lesser extent in miR-126 transduced cells. Aβ1-42 and NGF or sAPPα treatment caused upregulation of AKT, pAKT, ERK, pERK, GSK-3β, and to a lesser extent pGSK-3β in control cells. In contrast, except for pERK and pGSK-3β, miR-126 overexpressing neurons showed downregulation of these molecules. While the pAKT/AKT and pGSK-3β/GSK-3β ratios were largely unchanged, and the pERK/ERK ratios were reduced in the controls, miR-126 overexpressing cells had also unchanged pAKT/AKT, but increased pERK/ERK and pGSK-3β/GSK-3β ratios. In the miR-126 overexpressing cells sAPPα alone or in combination with NGF increased the pERK/ERK or pGSK-3β/GSK-3β ratios. *: p < 0.05 comparing treated to untreated condition. #: p < 0.05 comparing ratios for Syn.miR-126 to ratios of Syn.GFP controls.

50

100

150

200

50

100

150

200

50

100

150

200

- + - + - + - +

- - + + - - + +

- - - - + + + +

50

100

150

200

50

100

150

200

50

100

150

200

- + - + - + - +

- - + + - - + +

- - - - + + + +

50

100

150

200

50

100

150

200

50

100

150

200

- + - + - + - +

- - + + - - + +

- - - - + + + +

CAG.NGF Aβ1-42 sAPPα#

pAkt/Akt

Akt

pAkt

Syn.GFP Syn.miR-126#

Erk

pErk

pErk/Erk

GSK3β#

pGSK3β#

pGSK3β/GSK3β#

% E

xpre

ssio

n R

elat

ive

to

Unt

reat

ed C

ontro

l

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

# # # # #

* * *

*

* * *

* *

* * * * *

* *

*

*

* *

*

* *

*

* * * *

#

# #

# # #

# #

* * *

* * * *

* * * * * * *

* *

* *

* *

* * * * * *

*

#

#

# #

#

#

#

#

a b

50

100

150

200

- + - + - + - +

- - + + - - + +

- - - - + + + +

50

100

150

200

CAG.NGF Aβ1-42 sAPPα#

IRS-1

p85β#

Syn.GFP Syn.miR-126#

% E

xpre

ssio

n R

elat

ive

to

Unt

reat

ed C

ontro

l * *

* * *

*

* * * * *

*

* * * * * *

* *

* *

* * * *